BioSpace News Archive

The Thermo Scientific Multidrop Pico 1 and Pico 8 Digital Dispensers are designed to overcome the accuracy, cost and ergonomics challenges associated with manual pipetting

PharmaMar and Bionical Emas, a global specialist Clinical Research Organization have announced the launch of an Expanded Access Program for lurbinectedin to treat patients in the United States with relapsed Small Cell Lung Cancer, who are unable to enter clinical trials and there are no appropriate alternative treatments.

GeoVax Labs, Inc., a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, together with BravoVax, a vaccine developer in Wuhan, China, today announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus.

The company based the decision on safety information after unexpected serious adverse events, including one patient death in its Phase IIb CATALYST trial.

Pharma companies from across the globe provide updates on their pipelines and business.

Epygenix Therapeutics, Inc. announced that the Company successfully completed a Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to assess safety and pharmacokinetics of escalating single and multiple oral doses of EPX-100 in fasting healthy subjects and following a high-fat meal.

The Phase II multicenter, randomized, double-blind, placebo-controlled, dose-ranging study included 105 patients with hypertriglyceridemia, type 2 diabetes and NAFLD.

China’s National Health Commission stated today that the coronavirus has infected 5,974 individuals, resulting in 132 deaths and 103 people being cured.

Krystal Biotech and Foghorn Therapeutics are beginning 2020 with significant expansion projects.

The merged companies will operate under the name Histogen and trade on the Nasdaq Capital Market under a new ticker symbol.